Ultragenyx announced that the FDA has granted fast track designation and rare pediatric disease designation to UX007 for the treatment of long-chain fatty acid oxidation disorders, a group of genetic disorders in which the body is unable to convert long-chain fatty acids into energy.
https://thefly.com/landingPageNews.php?id=2893087
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.